Context. AZD4625 (AstraZeneca) is an oral inhibitor of KRAS G12C being developed for the treatment of advanced solid malignancies . As indicated for JDQ443, the KRAS G12C mutation presents the perfect “Achilles heel” for targeting a KRAS protein previously thought undruggable. The protein is a current hot topic in precision oncology , with [...]
4 minute read
May 13, 2022
AZD4625: An Oral KRAS(G12C) Inhibitor
AZD4625
oral KRAS(G12C) inhibitor oral efficacy in xenograft model from literature starting point and SBDD J. Med. Chem. AstraZeneca, Cambridge, UK
Reviewer: